An Experimental Therapeutics Study of a Monoclonal Antibody Against Interleukin 17A in Patients With Treatment-Resistant Depression
Latest Information Update: 23 Nov 2023
At a glance
- Drugs Ixekizumab (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 16 Nov 2023 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.
- 16 Nov 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.
- 16 Nov 2021 Status changed from not yet recruiting to recruiting.